An alternative approach for controllable action of PROTACs in cancer cells could be taking advantage of cancer-specific receptors or transporters, such as HER2 and FOLR1 (Scaranti et al., 2020) for the guided delivery of PROTACs into cancer, but not normal cells. Here, ERBB2 is linked to cancer.